PolyPeptide Group Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 5/6

PolyPeptide Group hat ein Gesamteigenkapital von €359.9M und eine Gesamtverschuldung von €91.7M, was einen Verschuldungsgrad von 25.5% ergibt. Die Gesamtaktiva und Gesamtpassiva betragen €665.0M bzw. €305.1M.

Wichtige Informationen

25.5%

Verhältnis von Schulden zu Eigenkapital

€91.72m

Verschuldung

Zinsdeckungsgrad	n/a
Bargeld	€48.48m
Eigenkapital	€359.92m
Gesamtverbindlichkeiten	€305.05m
Gesamtvermögen	€664.97m

Jüngste Berichte zur Finanzlage

PolyPeptide Group (VTX:PPGN) Is Making Moderate Use Of Debt

Oct 21

Does PolyPeptide Group (VTX:PPGN) Have A Healthy Balance Sheet?

Jun 19

Recent updates

PolyPeptide Group AG's (VTX:PPGN) Intrinsic Value Is Potentially 19% Below Its Share Price

Nov 11

Further Upside For PolyPeptide Group AG (VTX:PPGN) Shares Could Introduce Price Risks After 33% Bounce

Mar 14

PolyPeptide Group AG's (VTX:PPGN) Intrinsic Value Is Potentially 99% Above Its Share Price

Mar 13

PolyPeptide Group AG Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Mar 18

Investors Shouldn't Be Too Comfortable With PolyPeptide Group's (VTX:PPGN) Robust Earnings

Mar 23

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: PPGNDie kurzfristigen Aktiva des Unternehmens (€292.6M) übersteigen seine kurzfristigen Passiva (€183.6M).

Langfristige Verbindlichkeiten: PPGNDie kurzfristigen Vermögenswerte des Unternehmens (€292.6M) übersteigen seine langfristigen Verbindlichkeiten (€121.4M).

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: PPGNDie Nettoverschuldung im Verhältnis zum Eigenkapital (12%) wird als zufriedenstellend angesehen.

Schulden abbauen: PPGN Das Verhältnis von Schulden zu Eigenkapital ist in den letzten 5 Jahren von 30.5% auf 25.5% zurückgegangen.

Schuldendeckung: PPGNDie Schulden des Unternehmens sind gut durch den operativen Cashflow gedeckt (93%).

Zinsdeckung: Unzureichende Daten, um zu bestimmen, ob die Zinszahlungen von PPGN für seine Schulden durch das EBIT gut gedeckt sind.

PolyPeptide Group Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 5/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

PolyPeptide Group (VTX:PPGN) Is Making Moderate Use Of Debt

Does PolyPeptide Group (VTX:PPGN) Have A Healthy Balance Sheet?

Recent updates

PolyPeptide Group AG's (VTX:PPGN) Intrinsic Value Is Potentially 19% Below Its Share Price

Now 22% overvalued after recent price rise

PolyPeptide Group (VTX:PPGN) Is Making Moderate Use Of Debt

Sentiment Still Eluding PolyPeptide Group AG (VTX:PPGN)

Consensus EPS estimates fall by 16%

Consensus EPS estimates fall by 15%

Does PolyPeptide Group (VTX:PPGN) Have A Healthy Balance Sheet?

Consensus EPS estimates fall by 17%, revenue upgraded

Further Upside For PolyPeptide Group AG (VTX:PPGN) Shares Could Introduce Price Risks After 33% Bounce

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

PolyPeptide Group AG's (VTX:PPGN) Intrinsic Value Is Potentially 99% Above Its Share Price

New major risk - Share price stability

PolyPeptide Group AG, Annual General Meeting, Apr 09, 2025

PolyPeptide Group AG to Report First Half, 2025 Results on Aug 12, 2025

First half 2023 earnings: EPS and revenues exceed analyst expectations

Consensus EPS estimates fall from profit to €1.13 loss

New major risk - Share price stability

Consensus EPS estimates fall by 24%

Consensus EPS estimates fall by 17%

Consensus EPS estimates fall by 16%

PolyPeptide Group AG Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Full year 2022 earnings: EPS and revenues miss analyst expectations

Investor sentiment deteriorates as stock falls 21%

Consensus EPS estimates fall by 19%

PolyPeptide Group AG to Report First Half, 2024 Results on Aug 13, 2024

PolyPeptide Group AG Appoints Peter Wilden as Executive Chairman

Now 21% undervalued after recent price drop

Now 20% undervalued after recent price drop

Consensus forecasts updated

Consensus EPS estimates fall by 13%

Investor sentiment deteriorated over the past week

High number of new and inexperienced directors

Investor sentiment improved over the past week

PolyPeptide Group AG to Report Fiscal Year 2022 Results on Mar 14, 2023

Investor sentiment deteriorated over the past week

First half 2022 earnings: EPS and revenues miss analyst expectations

Investor sentiment deteriorated over the past week

Consensus EPS estimates fall by 11%

PolyPeptide Group AG to Report First Half, 2022 Results on Aug 19, 2022

Investor sentiment improved over the past week

Investor sentiment improved over the past week

High number of new and inexperienced directors

PolyPeptide Group AG Appoints Monika Casanova as Chief Human Resources Officer and Member of its Management Committee

PolyPeptide Group AG Approves Cash Distribution for the Year 2021, Payable on May 02, 2022

PolyPeptide Group AG Proposes Cash Distribution for the Year 2021

Investors Shouldn't Be Too Comfortable With PolyPeptide Group's (VTX:PPGN) Robust Earnings

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Investor sentiment deteriorated over the past week

Insufficient new directors

Insufficient new directors

Consensus EPS estimates increase to €1.57

PolyPeptide Group AG has completed an IPO in the amount of CHF 737.39136 million.

Analyse der Finanzlage

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Bilanz

Entdecken Sie finanziell stabile Unternehmen